SLC5A2 and cardiovascular disorder: T2DM is a complex, progressive metabolic disorder characterized by persistent hyperglycemia and associated with macrovascular and microvascular complications.[7] SGLT2 inhibitors can not only control glycemia but also reduce body weight and hypertension, which are particularly beneficial for T2DM accompanied by cardiovascular disease.[16] SGLT2 inhibitors are generally considered as second-line treatment after metformin in T2DM.